Before Capital Asks the Question: A Board Routine for Individual Dependency

Funding conversations have a way of turning informal assumptions into documented assertions. A management team may know that one person holds the commercial relationship with the largest customer, or that the finance director is the only person who can explain the covenant model. The board may not have tested what would happen if that person were unavailable. Before the next capital conversation, directors should turn that knowledge into a single page of evidence.

This is not a succession plan in miniature. It is a concentrated-dependency review: a structured way to identify where the company relies on an individual, test the depth of cover beneath them and agree actions that make the position defensible. It should be completed by the board, with management input, and revisited when roles, customers or financing arrangements change.

Why the question arrives late

Investors and lenders are alert to management continuity, but the enquiry often surfaces late in a funding round. By then, the board pack is complete, the forecast has been circulated and the legal workstreams are underway. A question about individual dependency can feel like an interruption rather than a governance issue.

It is better treated as part of the preparation. A UK board that can explain where the company is exposed, what cover exists and what actions are underway is in a stronger position than one that offers reassurance without evidence. The exercise also has value outside fundraising: it supports board oversight of operational resilience, regulatory continuity and the practical consequences of senior departures.

Start with the work, not the title

The first mistake is to map the organisation chart. Hierarchy matters, but dependency usually sits in access, knowledge and relationships. Begin instead with the work that would stop or materially slow if an individual were unavailable for a defined period. Thirty to sixty days is a useful planning horizon for the first pass.

Typical candidates include a founder who remains the principal product architect, a commercial director who owns the largest client relationship, a finance lead who controls cash forecasting and lender reporting, a regulated-function head whose approvals cannot be delegated informally, or a technical specialist whose know-how is not documented. The point is not to list every senior role. It is to identify the activities where substitution would be difficult and the consequences would be material.

A one-page test of depth

The output should fit on one page. A board can use a simple table with columns for the critical dependency, the named individual, the reason they are pivotal, the immediate cover, the evidence that cover has been tested, the residual risk and the agreed action with an owner and date. Ten entries are usually enough for a first review; a longer list tends to become a staff directory rather than a governance tool.

The evidence column is the discipline. A named deputy is not cover unless that person has the authority, access and experience to act. A colleague who has watched the process is not cover unless they have run it. An external adviser may provide credible support, but only if the arrangement is current, documented and available at short notice. Boards should distinguish between nominal cover and exercised cover.

Three tests before the board signs off

First, apply the substitution test. Could another named person perform the critical activity within the stated period without calling the absent individual? If the answer depends on informal help, the cover is not yet real.

Second, apply the evidence test. Has the cover been exercised through a planned absence, a simulation, a delegated approval or a documented handover? A board does not need exhaustive rehearsal, but it should be able to point to something more than an assumption.

Third, apply the counterparty test. Would the customer, lender, regulator or key supplier accept the substitute? Some dependencies are internal and can be managed by delegation. Others sit in relationships where the counterparty expects continuity of a particular person. That distinction affects both risk and mitigation.

What the page should change

The exercise is only useful if it produces decisions. Common actions include documenting critical processes, extending delegated authorities, introducing cross-training, adjusting notice periods, creating retention arrangements for pivotal roles and putting a communication plan in place for unexpected absences. Key-person insurance may be part of the financial response, but it is not operational cover. A payment does not keep a regulated function running or preserve a client relationship in the weeks after a departure.

The board should also decide who owns the page. In many companies, the audit committee or the board itself is the natural home, with management responsible for updating the evidence. The page should be reviewed before a funding round, after a senior appointment or departure, and when a major customer or financing arrangement changes. A short discussion in the board minutes is enough, provided it records the residual risks and the actions agreed.

Preparing for the funding-round conversation

When investors or lenders ask about management continuity, the board should be able to give a concise answer: these are the critical dependencies, this is the cover, this is what we have tested and these are the actions underway. If a dependency remains significant, say so and explain the mitigation. Overclaiming is worse than disclosing a known concentration with a credible plan.

Legal advisers should be involved where representations, warranties or disclosure schedules touch on management continuity. The board’s role is to ensure the factual position is accurate and that the company is not relying on a description of cover that has never been tested.

Common traps

Four traps recur. The first is confusing succession planning with immediate cover; a plan for next year does not help next month. The second is assuming a non-executive director can step into an executive role. The third is treating insurance as a substitute for operational resilience. The fourth is mapping only executive directors and overlooking specialist, commercial or regulated roles where dependency is concentrated.

A one-page dependency review will not eliminate the risk that a pivotal individual leaves or becomes unavailable. It will, however, give the board a clearer view of where the company is exposed, a record of what has been done and a more credible answer when capital asks the question.